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RESEARCH LETTERSAntenatally DiagnosedADPKD
To the Editor: Advances in antenatal ultrasonography
have substantially improved the counseling of pregnant
women.14 With this advancement comes a diagnostic
dilemma in the approach to antenatal diagnoses of cystic
kidney disease. The differential diagnosis of enlarged
cystic echogenic kidneys includes autosomal dominant
polycystic kidney disease (ADPKD), autosomal recessive
polycystic kidney disease, renal cysts and diabetes
syndrome, and other syndromic disorders.2,3,5
ADPKD is the most commonly inherited renal disease,
occurring in 1 in 400 to 1000 live births.1,3,4 Disease
progression is marked by growth of renal cysts, neph-
romegaly, and advancing renal dysfunction, ultimately
resulting in end-stage kidney disease in more than 50%
of patients in the fifth to sixth decade of life.24,612
Extrarenal manifestations include intracranial aneu-
rysms, cardiac valvular defects, diverticular disease, and
cysts in the liver, spleen, and pancreas.1,3,4,6,7
Mutations in 3 genes have been reported: PKD1
(16p13.3), responsible for 80% to 85% of cases; PKD2
(4q22.1), responsible for 10% to 15% of cases; and the
recently identified GANAB (11q12.3).1,3,4,5,814 Pa-
tients with PKD1 mutations have a poorer prognosis
than patients with PKD2 mutations, on average
reaching end-stage kidney disease at 55 versus 70
years, respectively.1,5,7,10,14
ADPKD is an autosomal dominant disorder with
100% penetrance and both intra- and interfamilial
variability in disease presentation and phenotype.4 A
“2-hit” hypothesis postulates that a germline
mutation inactivates one PKD1 allele whereas a
subsequent somatic mutation inactivates the other
allele, resulting in cyst formation.5,12,13 Because a
second somatic mutation is not identified in all renal
cysts, other genomic and nongenomic cystogenic
impacts have been suggested.5,12,13,15
Historically, ADPKD has been recognized as an
adult-onset disease; however, symptoms can manifest in
early childhood.13,6 Since the first report of fetal cases
in 1971, ADPKD has increasingly been diagnosed in
utero.2,3,6,11 Early diagnosis allows the opportunity for
close follow-up and monitoring of disease pro-
gression.24,6,11 Given the increasing diagnosis ofADPKD
in utero, it is desirable to form an approach so as to better
inform clinical practice and to counsel affected families.
The aim of our study was to review our antenatally
diagnosed cases of ADPKD and to describe their
phenotype during a short-term follow-up.1214Full methods are included as supplemental material
(Supplementary Methods).
RESULTS
An overview of our ADPKD cohort is shown in Table 1.
Six children were identified with a presumed diag-
nosis of ADPKD (Table 1) and were referred for tertiary
pediatric nephrology and genetics input from centers
in Queensland (population of 4.97 million).16 All 6
cases were included in the study based on the
antenatal ultrasonography findings of bilateral
nephromegaly and echogenic kidneys. Mean age at
referral was 22.6 weeks’ gestation (range, 20–33 þ 2
weeks). All children were born at term, had no
prenatal or postnatal complications, were well with
normal growth and development, and had bilaterally
enlarged and cystic kidneys (>3 cysts bilaterally) at
last follow up. Mean age at last follow-up was 10.6
months (range, 2.5–30 months).
One child had pyelonephritis at 4 months of age
requiring i.v. antibiotics. One child had a splenic cyst
noted at 4 months of age.
One subject had no known family history of ADPKD
(1/6). Parents of this subject had normal renal ultra-
sound results before the age of 40 years, and thus
ADPKD could not be confidently excluded. Genetic
testing identified two PKD1 variants: a de novo patho-
genic mutation (p.Lys2529Asn) and a paternally
inherited “variant of uncertain significance” (VOUS)
(p.Ser225Leu).
DISCUSSION
With increasing awareness of ADPKD and advance-
ments in imaging technology, more cases of ADPKD are
being diagnosed antenatally.24 We have experienced
an increase in referrals of antenatally diagnosed cases in
recent years.
Antenatal cystic kidneys are identified by ultrasound
imaging.2,4,5,10 Although the differential for echogenic or
cystic kidneys in utero remains broad, a focused family
history is able to delineate these.2,3,10 In the absence of a
positive family history, the distinction of ADPKD from
autosomal recessive polycystic kidney disease may be
difficult.1,2,5,10 Involvement of a multidisciplinary team
is essential for antenatal counseling and for guiding
postnatal management.12,17 Furthermore, early detection
of affected individuals facilitates timely implementation
of an anticipatory approach, particularly important with
potential emerging disease-modifying therapies.2,4,6,11
All children included in this report were appropriately
referred to a tertiary center and received timely multi-
disciplinary team review.Kidney International Reports (2018) 3, 1214–1221
Table 1. Clinical characteristics of children with antenatally diagnosed ADPKD
Clinical features Case 1 Case 2 Case 3 Case 4 Case 5 Case 6

























Age 20 wk GA 30 mo 20 wk GA 4 mo 20 wk GA 4 mo 20 wk GA 13 mo 33þ2 wk GA 2 mo 33þ5 wk GA 2 mo
Ultrasound findings
Cystic kidneys – þ þ þ – þ þ þ – þ þ þ
Number of cysts N/A >3 >3 >3 >3 >3 >3 >3 N/A >3 1 >3
Echogenic kidneys þ þ þ þ þ þ þ þ þ þ þ þ
Other anomalies – – – – – – – – – – – –
Kidney length
Left (centile) 85 >95 >95 >95 >95 >95 70 >95 50 >95 50 >95
Right (centile) >95 >95 >95 >95 >95 >95 85 >95 50 >95 50 >95
Genetic testing þ N/A N/A N/A N/A N/A
Urological complications – – – þ þ –
Systemic features – – þa – – –
Hypertension N/A – N/A – N/A – N/A – N/A – N/A –
Creatinine (mmol/l) N/A <30 N/A <30 N/A <30 N/A <30 N/A <30 N/A <30
Family history – þ þ þ þ þ
Number of first-degree
affected relatives
0 2 1 1 1 1
Number of second-degree
affected relatives
0 2 2 1 4 1
F, female; GA, gestational age; M, male; N/A, not applicable; þ, present; , absent.
aSplenic cyst.
RESEARCH LETTERSThe current pediatric approach to the management
of cystic kidneys includes annual clinical reviews and
intermittent ultrasonography.2,4,5,10 Once renal func-
tion declines, irreversible structural damage has
already been established.36,10 Regular screening of
affected individuals allows early diagnosis and treat-
ment of hypertension, review for potential systemic
complications, and enrollment into potential future
clinical trials of disease-modifying treatments.3,4,6,11
Gimpel et al. published recommendations on the
diagnosis, management, and follow-up of perinatal
cystic kidneys. They recommended phenotype-specific
timing of renal ultrasounds postnatally, and a referral
to clinical genetics for diagnostic counseling and
possible genetic testing.17 They found that fetuses with
bilateral hyperechogenic cystic kidneys, such as in our
cohort, have a good prognosis but significant risk of
long-term renal disease.17 To add further to the
recommendations from Gimpel et al., our approach is
to refer the parents of affected children to an adult
nephrologist (Figure 1).
The natural history of ADPKD is characterized by a
slow growth of the kidney cysts with few renal or
systemic complications until adulthood.1,3,6,9,10 Kidney
function and blood pressure usually remain normal
during childhood and adolescence,15,10 as in the case
of our cohort.
Previous studies have documented that patients
detected with ADPKD in utero or less than 18 months of
age have earlier progression to end-stage kidneyKidney International Reports (2018) 3, 1214–1221disease.1,9 On the other hand, Boyer et al. observed a
favorable long-term prognosis in prenatally diagnosed
ADPKD cases, at least until adolescence.1 Long-term
follow-up of our cohort is required to determine
outcomes.
Given the degree of phenotypic variability of
ADPKD, counseling of patients and parents can pre-
sent challenges.4,1114 Genetic testing is not routinely
performed. It is costly, time consuming, and not
universally available.3,4,7,11,12,14 Furthermore, legal
and regulatory frameworks guiding the use of genetic
information for insurance and employment remain
undefined in some jurisdictions.3,7,12 De Rechter et al.
reported that 37.1% of nephrologists advise against
genetic testing in childhood because of the adult onset
of ADPKD complications, fear of psychological stress,
and the lack of effective treatment.11 However,
genetic testing can assist in pediatric ADPKD cases
with no family history.4,12,14 A confirmed genetic
diagnosis can allow more targeted management and
accurate genetic counseling for parents and other
relatives.4,12,14
One of our subjects presented without a family
history of ADPKD, prompting diagnostic genetic
testing. This identified a de novo pathogenic mutation
and a paternally inherited VOUS in PKD1 gene.18 The
VOUS has been classified as such due to the following:
conflicting in silico predictions; a case report of an
ADPKD case stating it as “likely pathogenic”19,20; and
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Figure 1. Our approach to antenatally diagnosed autosomal dominant polycystic kidney disease (ADPKD). MDT, multidisciplinary team.
RESEARCH LETTERSmutation in another patient. Therefore, the VOUS could
be a benign finding or could suggest that the father is
also at risk for developing ADPKD. If this is a
functionally significant variant, it may explain the
more severe and earlier onset phenotype in the child
due to a 2-mutation hypothesis.1214
Pharmacological management of ADPKD is rapidly
evolving. Phase III clinical trials on the long-term
safety of tolvaptan in children with ADPKD have
commenced. Adult studies have demonstrated delayed
decline of kidney function in patients with rapidly
progressing ADPKD on tolvaptan.8,18 Early treatment
with angiotensin inhibitors to control hypertension
might minimize cardiovascular morbidity in ADPKD
patients.3,4 These emerging treatments may offer early
intervention to pediatric high-risk cases or those found
to have early disease progression.3,4,8 Furthermore,
they may alter the approach to antenatally diagnosed1216ADPKD and improve the prognosis of affected
families.3,4,8
In conclusion, ADPKD has become acknowledged
as a pediatric condition, with advancements in
ultrasonography resulting in increased diagnosis.
With this early recognition, clinicians and families
alike are faced with an uncertain future and prog-
nosis, requiring regular reviews for disease progres-
sion. Psychosocial outcomes including significant
treatment burden, fear of end-stage kidney disease,
and variable familial presentation are all realistic
concerns that affected individuals and families
face. Here we have presented a multidisciplinary
approach to and clinical progress of a cohort of
antenatally diagnosed cases of ADPKD. Emerging
disease-modifying medications may improve the
prognosis for these individuals and ultimately reduce
the disease burden in adulthood.Kidney International Reports (2018) 3, 1214–1221
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IntoxicationTo the Editor: Calcium oxalate crystal (CaOx) depo-
sition within the renal parenchyma is well described as1217
